Endometrial Hyperplasia Prevention — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for endometrial hyperplasia prevention. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
3
Active US patents
66/100
Avg vulnerability
—
Annual revenue covered

Originators in Endometrial Hyperplasia Prevention

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Ferring 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating endometrial hyperplasia prevention. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
29
1
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Endometrin
progesterone
 Ferring 3 66 — 2029-02-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10548904 Endometrin method of use 75 2029-02-03
8580293 Endometrin method of use 68 2030-01-21
10537584 Endometrin formulation 55 2029-02-03

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10537584 Endometrin formulation 55 2029-02-03
8580293 Endometrin method of use 68 2030-01-21
10548904 Endometrin method of use 75 2029-02-03

Related